Bo Cumbo, AavantiBio CEO

Scoop: A small gene ther­a­py biotech, flush with ex-Sarep­ta and blue­bird lead­ers, guts CMC

En route to en­ter­ing the clin­ic with its first AAV-based gene ther­a­py for a rare neu­ro­mus­cu­lar dis­ease, Aa­van­tiBio has let go of 30 em­ploy­ees, End­points News has learned.

The move comes af­ter a year stack­ing its ex­ec­u­tive bench with ex-Sarep­ta and blue­bird bio lead­ers and ink­ing mul­ti­ple part­ner­ships with the likes of Alde­vron, Catal­ent and Re­silience. The biotech al­so formed a sci­en­tif­ic ad­vi­so­ry board in Feb­ru­ary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.